Introduction:
Vitiligo is a skin condition in which part of the skin becomes shiny due to a lack of pigmentation. It is more visible than the surrounding skin. Vitiligo has a unique presentation for everyone affected.
UVBMEDI can help you get relief from this disorder. Vitiligo only appears on one side of the body. It can occur on one or both sides of the body, or it may be parallel.
What causes vitiligo?
Vitiligo affects men and women of all ages and skin tones. Our UVB phototherapy has the resources to diagnose vitiligo and determine if the underlying condition requires treatment.
This gradual process can result in the construction of damaged areas or new areas. While the condition itself is devastating, the psychological effects of vitiligo can impact quality of life. Vitiligo affects all skin types, races, ethnicities, and races. Psychosocial effects occur in many disorders, especially vitiligo, especially in blacks.
Can vitiligo be prevented or cured?
Vitiligo cannot be prevented or cured with the help of UVBMEDI products. Some chose to continue treatment; others found it unnecessary. Some hide it with clothes, jewelry, or sunglasses. Treatment can also help restore color to damaged areas.
A variety of light and laser treatments may be used as the disease progresses. Surgery is an option, but it is usually considered only if the vitiligo is in cosmetic areas, has not responded to other treatments and is stable.
Can UVB therapy help to treat vitiligo disease?
UV-based treatments have been the mainstay of vitiligo treatment for decades. The first method is phototherapy with sorrel and UVA (PUVA). Currently, NB-UVB and a targeted camera (excimer laser or excimer lamp) are used in a few places.
Psoralen and ultraviolet A
Several previous studies have shown PUVA to be an effective pigment restoration treatment for vitiligo. But it has some limitations. Taking Sorelen can cause diarrhea and, in rare cases, diarrhea.
UVA irradiation should be applied within 1-2 hours of psoralin ingestion, and eye and skin light protection should be performed after ingestion. Because UVA penetrates deeper than UVB, inappropriate use of PUVA can cause severe and painful rashes.
Long-term treatment (>400 cycles), such as psoriasis, can lead to lentigenization and photocarcinogenesis. In addition, it has been shown to be effective in vitiligo, with pigmentation disorders being reported at least at the end of treatment.
Narrowband UVB
NB-UVB provides better pigmentation parameters than PUVA and therefore has fewer side effects, making it the first drug for the treatment of generalized advanced vitiligo. Indeed, UVB phototherapy is the most powerful stimulus to activate melanocyte precursors and is considered safe for children and pregnant women.
- Treatment regimen
According to the recommendations of the Vitiligo Task Force, treatment should begin at a low dose (200 mJ/cm2), increasing the dose by 10% to 20% two to three times a week. If asymptomatic coagulopathy develops in less than 24 hours, the appropriate dose should be obtained and maintained until coagulation resolves.
The dose should be further increased by 10-20% until asymptomatic erythema returns. The acceptable dose for the face for treatment is 1500 MJ/cm2, while the normal dose for the body is 3000 MJ/cm2.
- Other dose and treatment modalities
Low-dose and intermittent therapies have been tried with good results. Many study compared conventional NB-UVB phototherapy with low-dose NB-UVB (the dose remains constant for six cycles before increasing) in patients with stable NSV, and the dose of UVB that escapes found in the head and neck reduces side effects.
NSV continued to use NB-UVB phototherapy, and it was concluded that there was no difference in clinically relevant treatment outcomes.
Targeted UVB phototherapy
Targeted phototherapy, also known as concentrated phototherapy or micro focused therapy, selectively targets individual skin lesions. This results in faster energy delivery at higher rates, shorter treatment counts, and faster processing.
If 10% of the body is affected, targeted radiographs may be considered. For paediatric patients, this has the added benefit of reducing feelings of isolation or anxiety in NB-UVB phototherapy.
- Excimer laser
The excimer laser emits at a wavelength of 308 nm and produces the same biological response as NB-UVB. The excimer laser appears to be the most effective treatment for SV when used in the early stages of clinical practice.
The treatment regimen varies from one to three times a week. If no response is seen after 20–30 treatments, multimodal treatment options should be considered. Excimer lasers have been reported to produce 75% repigmentation in 16–52% of patients.
- Excimer lamp
The excimer lamp uses the same wavelength as the excimer laser, 308 nm, but emits irregular, almost continuous light. Although both devices are equally effective for pigmentation of vitiligo lesions (30–33), excimer laser therapy is faster and takes longer to drive the same lamp current.
However, excimer lasers are more expensive and require additional costs. The UVBMEDI treatment is carried out one to three times a week for 24 weeks.
- Microfocused NB-UVB phototherapy
The process is similar to that of NB-UVB, but the energy can be used in smaller doses. In recent years, several targeted NB-UVB phototherapeutic agents have been introduced in the pharmaceutical industry.
These devices produce only visible and ultraviolet light that is filtered to absorb NB-UVB. The treatment schedule depends on the patient’s characteristics.
